TScan Therapeutics, Inc. (NASDAQ:TCRX) Position Trimmed by Renaissance Technologies LLC

Renaissance Technologies LLC trimmed its stake in TScan Therapeutics, Inc. (NASDAQ:TCRX) by 85.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,600 shares of the company’s stock after selling 63,400 shares during the quarter. Renaissance Technologies LLC’s holdings in TScan Therapeutics were worth $32,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the stock. Prudential Financial Inc. acquired a new stake in shares of TScan Therapeutics during the 4th quarter valued at $32,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of TScan Therapeutics during the fourth quarter worth $32,000. Wells Fargo & Company MN boosted its position in TScan Therapeutics by 41.1% during the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock valued at $59,000 after purchasing an additional 5,694 shares during the last quarter. Heck Capital Advisors LLC purchased a new position in TScan Therapeutics in the fourth quarter valued at about $61,000. Finally, SG Americas Securities LLC increased its position in TScan Therapeutics by 31.2% in the 4th quarter. SG Americas Securities LLC now owns 20,415 shares of the company’s stock worth $62,000 after purchasing an additional 4,852 shares during the last quarter. 82.83% of the stock is currently owned by institutional investors and hedge funds.

TScan Therapeutics Price Performance

NASDAQ TCRX opened at $1.38 on Friday. TScan Therapeutics, Inc. has a twelve month low of $1.02 and a twelve month high of $9.69. The stock has a market capitalization of $77.81 million, a PE ratio of -1.30 and a beta of 1.06. The stock has a 50-day simple moving average of $1.51 and a 200 day simple moving average of $2.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.02. The firm had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $1.62 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. Research analysts anticipate that TScan Therapeutics, Inc. will post -1.12 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Morgan Stanley reissued an “overweight” rating and issued a $10.00 price target on shares of TScan Therapeutics in a research note on Friday, March 14th. HC Wainwright dropped their price target on shares of TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday. Barclays reduced their price objective on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a research note on Friday, March 7th. Wedbush reissued an “outperform” rating and set a $7.00 target price on shares of TScan Therapeutics in a research report on Tuesday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $9.00 price target on shares of TScan Therapeutics in a research note on Tuesday, April 8th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, TScan Therapeutics has a consensus rating of “Buy” and an average price target of $8.50.

TScan Therapeutics Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.